Peer Review History

Original SubmissionFebruary 5, 2025
Decision Letter - Chika Onwuamah, Editor

-->PONE-D-25-05682-->-->Universal Test and Treat strategy effect on Kidney Function in Adults living with HIV in Zambia: A Six-Month Multicenter Retrospective Cohort Study-->-->PLOS ONE

Dear Dr. Siame,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The reviewers have made several suggestions for improvement, including pointing out contradicting data in different sections of the manuscript. Kindly review and resolve the issues raised.

Please submit your revised manuscript by May 02 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:-->

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Chika Kingsley Onwuamah, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include a copy of Table 1, which you refer to in your text on page 5.

3. Please remove all personal information, ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set.

Note: spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file.

Additional guidance on preparing raw data for publication can be found in our Data Policy (https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data ) and in the following article: http://www.bmj.com/content/340/bmj.c181.long.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->2. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

-->5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: The authors have reported their research findings in the manuscript titled "Universal Test and Treat strategy effect on Kidney Function in Adults living with HIV in Zambia: A Six-Month Multicenter Retrospective Cohort Study". I have the following comments/observations:

1. I suggest the authors should consider rephrasing the title to read "The effect of the universal test and treat strategy on the kidney function in adults living with HIV in Zambia: A six-month multi center cohort study".

2. The eGFR calculation formulae used as reported were CKD-EPI in the abstract, and MDRD in the body of the manuscript. The authors should clarify the formula that was actually used.

3. In the results section, basic characteristics of study participants (page 5, line 11), the authors mentioned that "a high proportion of participants were taking NNRTI and ABC/3TC regimens. This is similar to what is reported in table 1; however, in table 2, the authors reported 1,173 participants on TDF/XTC, while only 35 participants were on ABC/3TC. The authors need to resolve this discordant results.

4. The explanation by the authors to the fact that in the ATT era, participants commenced ART earlier, and did not have renal complications associated with HIV makes scientific sense. However, TDF-based regimens have been reported extensively in literature to be associated with renal impairment in older patients, patients with co-morbidities etc. So it is critical for the authors to clarify whether these cohorts of patients were predominantly on ABC/3TC or TDF/XTC.

Reviewer #2: Reviewer’s comments on the manuscript titled “ Universal Test and Treat strategy effect on Kidney Function in Adults living with HIV in Zambia: A Six-Month Multicenter Retrospective Cohort Study.”

1. Originality of value:

The study is original and will contribute to scientific knowledge and enrich the repository of knowledge on burden of kidney disease among patient living with HIV, its risk factors and how it can be prevented or detected early, particularly in the sub-Saharan African region. The abstract is concisely written while the introduction was appropriately described, and study objective was clearly defined.

2. Suitability and Soundness:

The methodology is appropriate and suitable for the study design.

3. Clarity of presentation:

The manuscript presentation and lay out is clear and easy to follow.

4. Areas requiring corrections:

None

Reviewer #3: This article about HIV and kidney disease is timely and pertinent because it highlights the potential for preventing kidney disease. The drawback is the use of eGFR as the sole indicator of kidney impairment. An important hallmark of kidney damage is proteinuria whci was not utilised in this patient. One understands the operational issues with regards to HIV treatment funding and implementation especially with laboratory tests. But if serum creatinine could be done, microalbuminuria/proteinuria could be done.

Older patients would have decline in kidney impairment as per eGFR estimation. Could could the authors provide summary on

of eGFR in the two groups in addition to using it as a cut-off point. Could the trend analysis be done since this since a cohort?

The explanation for kidney impairment among urban dwellers is far fetched, especially when this is not based on the data from the study. There is no evidence that these patients had hypertension or diabetes. It may just reflect the disproportionately large number of urban dwellers in the study.

**********

-->6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .-->

Reviewer #1: Yes:  Professor Oche O. Agbaji

Reviewer #2: Yes:  Yemi R. Raji

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

Review Comments to the reviewer.

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have reported their research findings in the manuscript titled "Universal Test and Treat strategy effect on Kidney Function in Adults living with HIV in Zambia: A Six-Month Multicenter Retrospective Cohort Study". I have the following comments/observations:

1. I suggest the authors should consider rephrasing the title to read "The effect of the universal test and treat strategy on the kidney function in adults living with HIV in Zambia: A six-month multi center cohort study".

Response: thank you for the suggestion. We have changed the title.

2. The eGFR calculation formulae used as reported were CKD-EPI in the abstract, and MDRD in the body of the manuscript. The authors should clarify the formula that was actually used.

Response: thank you for the suggestion. We have changed the title.

3. In the results section, basic characteristics of study participants (page 5, line 11), the authors mentioned that "a high proportion of participants were taking NNRTI and ABC/3TC regimens. This is similar to what is reported in table 1; however, in table 2, the authors reported 1,173 participants on TDF/XTC, while only 35 participants were on ABC/3TC. The authors need to resolve these discordant results.

Response: thank you for your observations. We have corrected this discordant results in the table.

4. The explanation by the authors to the fact that in the ATT era, participants commenced ART earlier, and did not have renal complications associated with HIV makes scientific sense. However, TDF-based regimens have been reported extensively in literature to be associated with renal impairment in older patients, patients with co-morbidities etc. So it is critical for the authors to clarify whether these cohorts of patients were predominantly on ABC/3TC or TDF/XTC.

Response: thank you. we have clarified in the results section and discussion section that most of participants in this study were on TDF/XTC and further discussed the results.

Reviewer #2: Reviewer’s comments on the manuscript titled “Universal Test and Treat strategy effect on Kidney Function in Adults living with HIV in Zambia: A Six-Month Multicenter Retrospective Cohort Study.”

1. Originality of value:

The study is original and will contribute to scientific knowledge and enrich the repository of knowledge on burden of kidney disease among patient living with HIV, its risk factors and how it can be prevented or detected early, particularly in the sub-Saharan African region. The abstract is concisely written while the introduction was appropriately described, and study objective was clearly defined.

2. Suitability and Soundness:

The methodology is appropriate and suitable for the study design.

3. Clarity of presentation:

The manuscript presentation and layout is clear and easy to follow.

4. Areas requiring corrections:

None

Response: thank you for appraisal of the manuscript.

Reviewer #3: This article about HIV and kidney disease is timely and pertinent because it highlights the potential for preventing kidney disease. The drawback is the use of eGFR as the sole indicator of kidney impairment. An important hallmark of kidney damage is proteinuria whci was not utilised in this patient. One understands the operational issues with regards to HIV treatment funding and implementation especially with laboratory tests. But if serum creatinine could be done, microalbuminuria/proteinuria could be done.

Older patients would have decline in kidney impairment as per eGFR estimation. Could could the authors provide summary on

of eGFR in the two groups in addition to using it as a cut-off point. Could the trend analysis be done since this since a cohort?

Response: thank you. We have now provided the summary of eGFR at baseline and at the endline of the study. Unfortunately, we are unable to do the trend analysis due to the nature in which the study was conducted. We only collected data at two points at baseline of the study and at 6 months. In addition, our result in tables two and three point to the fact that older individuals were at risk of kidney impairment.

The explanation for kidney impairment among urban dwellers is far-fetched, especially when this is not based on the data from the study. There is no evidence that these patients had hypertension or diabetes. It may just reflect the disproportionately large number of urban dwellers in the study.

Response: thank you. We have revised the explanation of as observed, indeed this was might have been a reflection due to disproportionately large numbers of urban dwellers in this study.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Chika Onwuamah, Editor

The effect of the universal test and treat strategy on the kidney function in adults living with HIV in Zambia: A six-month multi center cohort study

PONE-D-25-05682R1

Dear Dr. Siame,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Chika Kingsley Onwuamah, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

-->Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.-->

Reviewer #1: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

-->2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. -->

Reviewer #1: Yes

Reviewer #3: Yes

**********

-->3. Has the statistical analysis been performed appropriately and rigorously? -->

Reviewer #1: Yes

Reviewer #3: Yes

**********

-->4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.-->

Reviewer #1: Yes

Reviewer #3: Yes

**********

-->5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.-->

Reviewer #1: Yes

Reviewer #3: Yes

**********

-->6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)-->

Reviewer #1: The authors have addressed all issues raised by me in the revised manuscript. The manuscript has been revised accordingly.

Reviewer #3: (No Response)

**********

-->7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .-->

Reviewer #1: Yes:  Oche Ochai Agbaji

Reviewer #3: No

**********

Formally Accepted
Acceptance Letter - Chika Onwuamah, Editor

PONE-D-25-05682R1

PLOS ONE

Dear Dr. Siame,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Chika Kingsley Onwuamah

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .